Novo Nordisk
Canvas Category OEM : Pharmaceutical
For almost 100 years, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems, like our insulin pens. Our treatments today are benefiting millions of people living with diabetes, obesity, and rare blood and endocrine diseases. From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to patients throughout the world.
Assembly Line
CIRCTEC secures €150M to construct Europe’s largest end-of-life tyre pyrolysis recycling facility in the Netherlands
CIRCTEC, a company specialising in pyrolysis for sustainable end-of-life tyre recycling, announced that it has secured €150M in a fresh financing round co-led by Novo Holdings and A.P. Moller Holding. The funding includes a €75M equity investment from Novo Holdings and A.P. Moller Holding, along with €22.5M in grants awarded by the Government of the Netherlands.
The capital will enable CIRCTEC to establish Europe’s largest end-of-life tyre pyrolysis recycling facility in Delfzijl, the Netherlands. Once operational at full capacity, the facility will be capable of processing approximately 5 per cent of the 3.6M tons of end-of-life tyres generated annually in Europe.
REDUCED secures EUR 6 million financing led by Novo Holdings to scale its natural food ingredients business
REDUCED, a Copenhagen-based company that uses fermentation technology to transform food and agriculture industry side streams into natural food ingredients, today announced it has secured EUR 6 million in new financing. The funds were raised from a range of investors, including new investment from Novo Holdings and the Nordic flavour house Einar Willumsen, as well as existing investors EIFO and Rockstart Agrifood.
Proceeds from the round will be used to further develop its technology platform, broaden its portfolio of savoury ingredients, secure production capacity, implement certifications, and increase sales and marketing efforts.
EIFO and Novo Holdings lead €14M round in Power-to-Peroxide pioneer HPNow
HPNow, the pioneer in electrification of the hydrogen peroxide industry, announced the successful closing of a €14M round. The equity round is led by The Export and Investment Fund of Denmark (EIFO) together with Novo Holdings. Other investors in the round include MatiTech – a sustainable water treatment solution provider in Sub Sahara, and existing investors Evonik Venture Capital and AP Ventures.
HPNow’s breakthrough electrochemical technology enables the safe and sustainable generation of a powerful green oxidant directly on site, using only water and electricity as inputs. The output solution breaks down to pure water and oxygen following use. HPNow is bringing to market a greener alternative to the conventional fossil-fuel based centralized production, transportation and handling of bulk hydrogen peroxide, offsetting as much as three tons of CO2eq per ton of hydrogen peroxide generated on site, compared to standard production techniques.
Proceeds from this round of financing will primarily be used towards the scaling up of HPNow’s marketing, sales, technical support and production capacity, in order to address growing market demand.
Novo hires Thermo Fisher as second manufacturer for Wegovy weight-loss drug
Novo Nordisk (NOVOb.CO) has hired Thermo Fisher (TMO.N) as its second contract manufacturer for its hugely popular weight-loss drug Wegovy, a source familiar with the matter told Reuters. Thermo is doing the filling of the Wegovy injection pens at its factory in Greenville, North Carolina, the source said, declining to be named because the information is confidential.
Bactolife Raises EUR 30 million in Series A Financing
Bactolife A/S (“Bactolife”), a bioindustrial company developing proprietary Binding ProteinsTM, which strengthen the gut microbiome of humans and animals with the aim of reducing the burden of gastrointestinal infections and anti-microbial resistance, today announced that it has successfully raised EUR >30 million since its April 2021 seed round.
The financing round is led by ATHOS with participation from the Bill & Melinda Gates Foundation and existing investors, incl. Novo Holdings. Proceeds from the financing will enable Bactolife to advance its most mature projects towards commercial launch and strengthen the technology platform and upscaling capabilities. By doing so, the company aims at retaining its first mover advantage to transform human and animal health with target specific Binding Proteins™.
MiR500 at Novo Nordisk
Novo Nordisk and Microsoft collaborate to accelerate drug discovery and development using big data and artificial intelligence
Novo Nordisk and Microsoft have entered a new strategic collaboration to combine Microsoft’s computational services, cloud and artificial intelligence (AI) with Novo Nordisk’s drug discovery, development and data science capabilities.
Through the partnership, Microsoft is providing AI technology, foundational science models and expertise and is working alongside Novo Nordisk’s data scientists and domain experts from early research and development areas to accelerate Novo Nordisk’s R&D.
HoloLens 2 helps Novo Nordisk employees see work in new ways
The pharmaceutical giant, a leader in the global production of diabetes medicine, has been pioneering the use of emerging digital technologies for everything from simplifying floor operations in their manufacturing facilities across the globe to conducting virtual site visits from thousands of miles away. Some of those solutions include Microsoft HoloLens 2, Microsoft Dynamics 365 Remote Assist, Microsoft Dynamics 365 Guides and Microsoft Power Platform. This includes introducing what is known as augmented instructions, via HoloLens 2, to shop floor employees, providing them with new possibilities to support both process performance and getting onboarded for new procedures.